Raptor Pharmaceutical (RPTP) Soars On Positive Interim Phase 2a Clinical Data

October 12, 2009 9:21 AM EDT

This morning, Raptor Pharmaceutical Corp. (Nasdaq: RPTP) (Nasdaq: RPTPD) announced positive findings from the completed treatment phase of its open-label Phase 2a clinical trial of delayed-release cysteamine bitartrate in adolescent patients with non-alcoholic steatohepatitis, a progressive form of liver disease believed to affect 2% to 5% of the U.S. population.

At the completion of the initial six-month treatment phase, the study achieved the primary endpoint: mean blood levels of alanine aminotransferase, a common biomarker for NASH, were reduced by over 50%. Additionally, over half of the study participants had achieved normalized ALT levels by the end of the treatment phase.

Shares of RPTPD are up nearly 50% in pre-open action on the news.

Related Categories

FDA
Momentum Movers

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?